Long-term combination antipsychotic treatment in VA patients with schizophrenia.

Schizophrenia Research
Julie KreyenbuhlFrederic C Blow

Abstract

Treatment guidelines consider antipsychotic monotherapy the standard of care for patients with schizophrenia. However, previous studies have reported widely varying, and sometimes high, rates of antipsychotic polypharmacy. We identified 61,257 VA patients with schizophrenia in fiscal year 2000 who had >or=90 non-institutionalized days and one or more fills of antipsychotic medications. We used criteria of increasing stringency (>or=30, >or=60, or >or=90 overlapping days' supply of antipsychotic medications) and several cross-sectional criteria from previous studies to compare the prevalence of antipsychotic polypharmacy using these definitions. We also describe specific treatment combinations among patients receiving long-term polypharmacy. The prevalence of antipsychotic polypharmacy was 20.0%, 13.1%, and 9.5% when defined by a >or=30, >or=60, or >or=90-day overlap, respectively. Cross-sectional definitions used in previous studies did not identify 32-89% of patients receiving long-term polypharmacy (>or=90 days). In addition, approximately half of patients identified by cross-sectional criteria had only short-term overlaps of antipsychotic medications. Among patients receiving long-term polypharmacy, 74% received a first- and...Continue Reading

References

Jan 1, 1989·Psychopharmacology·W Z PotterW W Yan
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·R ShilohA Weizman
Feb 2, 1999·The British Journal of Psychiatry : the Journal of Mental Science·J L WaddingtonA Kinsella
Aug 24, 1999·The Journal of Clinical Psychiatry·S M Stahl
Sep 1, 2000·Alcoholism, Clinical and Experimental Research·F C Blow
Mar 6, 2003·Pharmacoepidemiology and Drug Safety·Ari B Jaffe, Jerome Levine
Mar 29, 2003·Psychiatric Services : a Journal of the American Psychiatric Association·George F Parker
Jun 26, 2003·The Journal of Clinical Psychiatry·Raymond P Tempier, Nicole H Pawliuk
Nov 25, 2003·The Journal of Clinical Psychiatry·Robert E McCueLeonel Urcuyo
Jan 30, 2004·Pharmacopsychiatry·R M Procyshyn, B Thompson
Apr 2, 2004·The American Journal of Psychiatry·Franca CentorrinoRoss J Baldessarini
Dec 31, 2004·The American Journal of Psychiatry·Richard C JosiassenRita A Shaughnessy
Jan 12, 2005·The Journal of Clinical Psychiatry·Michael J Sernyak, Robert Rosenheck
Aug 24, 2005·Human Psychopharmacology·Franca CentorrinoRoss J Baldessarini
Feb 2, 2006·The British Journal of Psychiatry : the Journal of Mental Science·Matti JoukamaaVille Lehtinen
Feb 3, 2006·The New England Journal of Medicine·William G HonerUNKNOWN Clozapine and Risperidone Enhancement (CARE) Study Group

❮ Previous
Next ❯

Citations

May 17, 2012·BMC Psychiatry·Miguel BernardoAntoni Serrano-Blanco
Apr 7, 2007·Psychiatric Services : a Journal of the American Psychiatric Association·Julie A KreyenbuhlFrederic C Blow
Nov 14, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeffrey A LiebermanUNKNOWN MEM-MD-29 Study Group
Apr 23, 2013·Psychiatry Research·Taishiro KishimotoChristoph U Correll
Jan 26, 2010·Community Mental Health Journal·Robert J ConstantineRajiv Tandon
Sep 26, 2012·Social Psychiatry and Psychiatric Epidemiology·Jaana T SuokasJari Tiihonen
Aug 30, 2012·The Psychiatric Clinics of North America·Christoph U Correll, Juan A Gallego
Aug 3, 2012·Revista de psiquiatrí́a y salud mental·Eliseo IniestaDavid Fraguas
Aug 10, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Dimitrios KontisEleftheria Tsaltas
Sep 8, 2009·Research in Social & Administrative Pharmacy : RSAP·Rajender R AparasuVinod Bhatara
Oct 31, 2006·Schizophrenia Research·Christoph U CorrellPeter Manu
Mar 26, 2014·Pharmacoepidemiology and Drug Safety·Emily Leckman-WestinMolly Finnerty
May 16, 2013·The International Journal of Neuropsychopharmacology·Nitin TotejaChristoph U Correll
Jan 8, 2009·The Annals of Pharmacotherapy·Bradley C MartinBetsy Lynn Sleath
Jul 29, 2015·Clinical Schizophrenia & Related Psychoses·Deanna L KellyReza Ghodssi
Oct 13, 2018·The Australian and New Zealand Journal of Psychiatry·Hong QiuWentian Dong
Sep 20, 2011·Journal of Psychiatric Practice·Christian R Dolder, Jonathan McKinsey
Jan 17, 2007·Journal of Clinical Psychopharmacology·Julie Marchand, Sylvain Grignon
Dec 22, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Constantin TranulisEmmanuel Stip
Apr 16, 2014·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·FangFang SunSandra B Morissette
Jan 8, 2020·Basic & Clinical Pharmacology & Toxicology·Lone Baandrup
May 28, 2020·International Journal of Psychiatry in Clinical Practice·Nađa P MarićNikolina Jovanović
Nov 8, 2012·Journal of Clinical Psychopharmacology·Yu-Tao XiangNaotaka Shinfuku
Dec 1, 2020·Expert Opinion on Pharmacotherapy·Justin FadenLeslie Citrome
Dec 22, 2020·Focus : Journal of Life Long Learning in Psychiatry·Adriana Foster, Jordanne King
Apr 28, 2021·Journal of Clinical Psychopharmacology·Anthony J Rothschild
Oct 25, 2008·Joint Commission Journal on Quality and Patient Safety·Jessica L GörenRichard C Hermann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

© 2022 Meta ULC. All rights reserved